These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
372 related articles for article (PubMed ID: 18157013)
1. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. Weng DS; Zhou J; Zhou QM; Zhao M; Wang QJ; Huang LX; Li YQ; Chen SP; Wu PH; Xia JC J Immunother; 2008 Jan; 31(1):63-71. PubMed ID: 18157013 [TBL] [Abstract][Full Text] [Related]
2. [Short-term curative efficacy of cytokine-induced killer cells combined micro-invasive treatments on hepatocellular carcinoma]. Zhou QM; Wu PH; Zhao M; Wang QJ; Huang LX; Li YQ; Chen SP; Xia JC Ai Zheng; 2006 Nov; 25(11):1414-8. PubMed ID: 17094912 [TBL] [Abstract][Full Text] [Related]
3. [Identification of immunological effector cells after autologous cytokine-induced killer cells treatment and its clinical implication in hepatocellular carcinoma patients]. Shi M; Zhang B; Tang ZR; Lei ZY; Wang HF; Feng YY; Liu JC; Fan ZP; Li HW; Mu JS; Wang FS Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2049-53. PubMed ID: 14703414 [TBL] [Abstract][Full Text] [Related]
4. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Jiang J; Xu N; Wu C; Deng H; Lu M; Li M; Xu B; Wu J; Wang R; Xu J; Nilsson-Ehle P Anticancer Res; 2006; 26(3B):2237-42. PubMed ID: 16821594 [TBL] [Abstract][Full Text] [Related]
5. [Cytokine-induced killer cell fusion to lower recurrence of hepatocellular carcinoma after transcatheter arterial chemoembolization sequentially combined with radiofrequency ablation: a randomized trial]. Zhao M; Wu PH; Zeng YX; Xia JC; Zhang FJ; Xian LJ; Zhang YP; Zhou K; Fan WJ; Zhang L; Gao F; Zhou QM Zhonghua Yi Xue Za Zhi; 2006 Jul; 86(26):1823-8. PubMed ID: 17054858 [TBL] [Abstract][Full Text] [Related]
6. [Growth inhibition of human hepatocellular carcinoma xenograft in nude mice by combined treatment with human cytokine-induced killer cells and chemotherapy]. Shi M; Yao L; Wang FS; Lei ZY; Zhang B; Li WL; Liu JC; Tang ZR; Zhou GD Zhonghua Zhong Liu Za Zhi; 2004 Aug; 26(8):465-8. PubMed ID: 15555334 [TBL] [Abstract][Full Text] [Related]
7. Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients. Huang ZM; Li W; Li S; Gao F; Zhou QM; Wu FM; He N; Pan CC; Xia JC; Wu PH; Zhao M J Immunother; 2013 Jun; 36(5):287-93. PubMed ID: 23719239 [TBL] [Abstract][Full Text] [Related]
8. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Leemhuis T; Wells S; Scheffold C; Edinger M; Negrin RS Biol Blood Marrow Transplant; 2005 Mar; 11(3):181-7. PubMed ID: 15744236 [TBL] [Abstract][Full Text] [Related]
9. Serum alpha-fetoprotein measurement in predicting clinical outcome related to autologous cytokine-induced killer cells in patients with hepatocellular carcinoma undergone minimally invasive therapy. Pan CC; Huang ZL; Li W; Zhao M; Zhou QM; Xia JC; Wu PH Chin J Cancer; 2010 Jun; 29(6):596-602. PubMed ID: 20507732 [TBL] [Abstract][Full Text] [Related]
10. Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma. Kim HM; Lim J; Yoon YD; Ahn JM; Kang JS; Lee K; Park SK; Jeong YJ; Kim JM; Han G; Yang KH; Kim YJ; Kim Y; Han SB Int Immunopharmacol; 2007 Dec; 7(13):1793-801. PubMed ID: 17996690 [TBL] [Abstract][Full Text] [Related]
11. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. Sangiolo D; Martinuzzi E; Todorovic M; Vitaggio K; Vallario A; Jordaney N; Carnevale-Schianca F; Capaldi A; Geuna M; Casorzo L; Nash RA; Aglietta M; Cignetti A Int Immunol; 2008 Jul; 20(7):841-8. PubMed ID: 18469328 [TBL] [Abstract][Full Text] [Related]
12. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Hui D; Qiang L; Jian W; Ti Z; Da-Lu K Dig Liver Dis; 2009 Jan; 41(1):36-41. PubMed ID: 18818130 [TBL] [Abstract][Full Text] [Related]
14. [Clinical effects of dendritic cells pulsed with autologous hepatoma cell lysates on the postoperative recurrence and metastasis of hepatocellular carcinoma]. Gao J; Chen M; Ren H Zhonghua Gan Zang Bing Za Zhi; 2005 Jun; 13(6):432-5. PubMed ID: 15975277 [TBL] [Abstract][Full Text] [Related]
15. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Lee JH; Lee JH; Lim YS; Yeon JE; Song TJ; Yu SJ; Gwak GY; Kim KM; Kim YJ; Lee JW; Yoon JH Gastroenterology; 2015 Jun; 148(7):1383-91.e6. PubMed ID: 25747273 [TBL] [Abstract][Full Text] [Related]
16. Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer. Sun Z; Shi L; Zhang H; Shao Y; Wang Y; Lin Y; Li X; Bai C Clin Immunol; 2011 Jan; 138(1):23-32. PubMed ID: 21041120 [TBL] [Abstract][Full Text] [Related]
17. [Effects of auto-tumor infiltrating lymphocytes induced by interleukin (IL)-12 with IL-2 on patients of primary hepatic carcinoma]. Zhang YX; Wang XY; Liu JB; Zhang SQ; Chen YR Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(14):973-6. PubMed ID: 18756970 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic safety and effects of adjuvant autologous RetroNectin activated killer cell immunotherapy for patients with primary hepatocellular carcinoma after radiofrequency ablation. Ma H; Zhang Y; Wang Q; Li Y; He J; Wang H; Sun J; Pan K; Chen M; Xia J Cancer Biol Ther; 2010 Jun; 9(11):903-7. PubMed ID: 20364106 [TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of cytokine-induced killer cells in nude mouse xenograft model. Kim HM; Kang JS; Lim J; Kim JY; Kim YJ; Lee SJ; Song S; Hong JT; Kim Y; Han SB Arch Pharm Res; 2009 May; 32(5):781-7. PubMed ID: 19471894 [TBL] [Abstract][Full Text] [Related]
20. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2]. Kanai T; Monden M; Takeda T; Gotoh M; Sakon M; Umeshita K; Hasuike Y; Sakita I; Nakano H; Yoshida T Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]